Latest Atheroma Stories
- More than 18 Million Brazilians have Reimbursable Access to MGuard EPS - BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard(TM) Coronary Embolic Protection Stent (EPS) from UNIMED, Brazil's largest private health care insurer. Alan Milinazzo, InspireMD's President and CEO said,...
Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, an established treatment for cancer patients, could offer a novel therapeutic approach to decrease levels of inflammation in the atherosclerotic plaques of patients with cardiovascular disease (CVD), reported an abstract¹ study at the International Conference on Nuclear Cardiology and Cardiac CT, May 5 to 8 in Berlin, Germany. "Our results should act as a stimulus for further exploration of radionuclide...
Heart disease and approximately half of all strokes are the results of advanced atherosclerosis with damaged endothelium, the inner lining of blood vessels. In 2009, the direct and indirect annual cost of heart disease and stroke was approximately $312.6 billion. Projections are for the total cost of heart disease to increase from $523 to $1.126 billion from 2013 to 2030. And by 2030, it is expected that there will be more than 148 million of the US population would have heart disease....
IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX CALGARY, April 18, 2013 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low HDL and ApoA-I (n=324). These target...
Dr. Stephen Nicholls named as Chair of Clinical Advisory Board IRVINE, Calif., April 11, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Stephen Nicholls, M.B.B.S., PhD., Heart Disease Theme leader at the South Australia Health and Medical Research Institute (SAHMRI), has been appointed as chair of the newly...
CARLSBAD, Calif., April 3, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-APOA(Rx), an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis. Apolipoprotein(a) contributes to the formation of plaque in arteries through its attachment to an LDL-C particle in a complex termed lipoprotein(a), or Lp(a). High levels of Lp(a) are associated with an increased risk of...
TEL-AVIV, Israel, March 15, 2013 /PRNewswire/ -- InspireMD's Carotid Embolic Protection Stent, based on InspireMD's proprietary MicroNet[TM] mesh technology, is designed to provide procedural and post-procedural distal embolic protection in Carotid Artery Stenting(CAS) procedures and there by reduce risk of stroke events. InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) Embolic Protection Stent (EPS), announced today that the...
Lawrence LeBlond for redOrbit.com - Your Universe Online Modern lifestyle factors – those that include smoking, eating fatty foods and lack of exercise – have been associated with unhealthy hearts for decades. But a new study in The Lancet suggests this decades-old health issue is in fact much older – at least 4,000 years older. The evidence comes from CT scans of ancient mummies, where researchers found calcification in their arteries, which suggests hardening of the arteries...
The Society for Heart Attack Prevention and Eradication (SHAPE) (http://www.shapesociety.org) promotes public awareness for early detection of heart attacks and stroke by introducing the Valentie™ a fashionable red tie with a stylistic heart motif that is indicative of SHAPE's healthy heart mission. Houston, TX (PRWEB) February 08, 2013 The Society for Heart Attack Prevention and Eradication (SHAPE) (http://www.shapesociety.org), a nonprofit organization that promotes public...
IRVINE, Calif., Nov. 15, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that it has received a Notice of Issuance for its patent application for Dissolution of Arterial Plaque. This patent issuance is the first major step in the development of the Company's intellectual property involving lipid...
